Seeking Alpha

Isis Pharmaceuticals (ISIS -5.5%) says it's earned a $10M milestone payment from AstraZeneca's...

Isis Pharmaceuticals (ISIS -5.5%) says it's earned a $10M milestone payment from AstraZeneca's (AZN) decision to add a second development candidate to their collaboration on cancer antisense drugs. ISIS had struck the deal in December to develop therapeutics against five cancer targets, including an exclusive license for AZN to develop ISIS-STAT3, a drug ISIS was evaluating for treating advanced lymphoma. It's now adding a second development candidate, ISIS-AR(Rx), to the collaboration.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|